share_log

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate

Benzinga Real-time News ·  Aug 4, 2022 21:10

Here's a roundup of top developments in the biotech space over the last 24 hours:

Stocks In Focus

AstraZeneca/Merck's Lynparza Scores European Approval In Early Breast Cancer

The European Union has approvedAstraZeneca Plc(NASDAQ:AZN) andMerck & Co Inc's(NYSE:MRK) Lynparza (olaparib) for human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.

The approval for Lynparza comes as monotherapy or in combination with endocrine therapy for the adjuvant treatment in the breast cancer setting with germline BRCA1/2 mutations.

Syros Bone Marrow Cancer Candidate Poised To Get European...

Login or create a forever free account to read this news
Sign up/Log in
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment